The Proceedings on Cancer-Immuno-Oncology offers the opportunity to publish emerging technologies, sharing experience, evaluate developments and future necessities in immuno oncology across industry and academia, and influence next-generation immunotherapy programs.

Ever since this years nobel prize in medicine has been awarded to James Allison und Tasuku Honjo for major steps in immunotherapy it becomes obvious: this topic is very important and it has found its way into daily clinical practice. Yet there still are so many unsolved questions, that across the different fields of specialties there is one common denominator and that is the need for further development taking the initial steps of successful treatment to immunotherapy 2.0.

This proceedings aims to bring together and enlighten the different major fields of microbiota, new targets, liquid biopsies, new ideas of players in the immune response, new therapeutic strategies, new combinatorial approaches bringing together some of the many different ways to unravel the immune systems own power in elimination of cancer cells.

The Proceedings on Cancer-Immuno-Oncology covers basic science developments across the cancer entities focussing on:

  •  Emerging immuno-oncology targets,
  •  Combination immunotherapies,
  •  Preclinical and translational IO,
  •  Mechanisms of IO resistence,
  •  IO predictive biomarkers,
  •  Immunoprofiling,
  •  Microbiome-Immuno-Interplay,
  •  Personalized cancer vaccines.

Conference Website: